Letroman (Letrozole)

Letrozole reversibly binds to the aromatase enzyme’s heme group, blocking the conversion of adrenal and peripheral androgen precursors into estrone and estradiol. This inhibition sharply reduces circulating estrogen levels, depriving estrogen‑dependent tumor cells of the hormonal stimulus required for growth.

The dosage of Letroman is determined by the prescribing clinician based on the individual’s clinical condition, treatment stage, and tolerability. Standard regimens typically involve a once‑daily oral dose, but the exact amount and schedule must be set by a qualified health‑care professional.

Letroman is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as the drug may be excreted in milk and affect the infant.

To order Letroman, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to letrozole is anastrozole, another aromatase inhibitor. Both lower estrogen levels, but letrozole is generally considered slightly more potent on a milligram‑for‑milligram basis. Choice between them depends on physician preference, patient tolerance, drug‑interaction profile, and specific clinical guidelines.

Letroman tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct light, and avoid exposure to excessive heat. No refrigeration is required for this oral formulation.

Letroman is taken orally, usually as a single tablet swallowed whole with water. It can be taken with or without food, but consistency with regard to meals helps maintain stable absorption. Patients should follow the dosing schedule prescribed by their health‑care provider.

The most serious adverse effects include severe bone loss leading to osteoporosis or fractures, liver dysfunction manifested by elevated enzymes or hepatitis, and rare cardiovascular events such as thromboembolism or stroke. Regular monitoring of bone density, liver function tests, and cardiovascular status is advised.

Letroman should not be used by pregnant or breastfeeding women, by patients with known hypersensitivity to letrozole or other aromatase inhibitors, and generally not by premenopausal women because its estrogen‑lowering effect is ineffective in that population. Caution is also advised in patients with severe liver impairment.